Key result
Among hospitalized patients with metastatic cancer, venous thromboembolism occurred in 6.6% of patients and was associated with significantly higher odds of in-hospital mortality (OR 1.50).
Cross-Sectional (n=850,570)
Yes
Effect estimate: OR 1.50 (95% CI 1.38-1.63)
Absolute Event Rate: 12.4% vs 8.6%
p-value: p=<0.001
VTE affects 6.6% of hospitalized patients with metastatic cancer and is associated with significantly increased in-hospital mortality and prolonged length of stay.
VTE was associated with higher in-hospital mortality in metastatic cancer; hypothesis-generating for targeted prophylaxis trials.
Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. 1,2 Patients with cancer and VTE have a lower survival rate; Sorensen et al 1 reported a 1-year survival rate of 12% in patients with VTE compared with 36% of those without. Additionally, patients with cancer and VTE are at a 4-to 8-fold higher risk of death relative to those without cancer. During hospitalization, patients with
No takes yet. Share an insight, caveat, or question.
Mohammed et al. (2018) conducted a cross-sectional in Metastatic Cancer (n=850,570). Venous thromboembolism (VTE) vs. No VTE was evaluated on In-hospital mortality (OR 1.50, 95% CI 1.38-1.63, p=<0.001). Among hospitalized patients with metastatic cancer, venous thromboembolism occurred in 6.6% of patients and was associated with significantly higher odds of in-hospital mortality (OR 1.50).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: